Hyperoxemia and excess oxygen use in early acute respiratory distress syndrome: insights from the LUNG SAFE study
verfasst von:
Fabiana Madotto, Emanuele Rezoagli, Tài Pham, Marcello Schmidt, Bairbre McNicholas, Alessandro Protti, Rakshit Panwar, Giacomo Bellani, Eddy Fan, Frank van Haren, Laurent Brochard, John G. Laffey, for the LUNG SAFE Investigators and the ESICM Trials Group
Concerns exist regarding the prevalence and impact of unnecessary oxygen use in patients with acute respiratory distress syndrome (ARDS). We examined this issue in patients with ARDS enrolled in the Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG SAFE) study.
Methods
In this secondary analysis of the LUNG SAFE study, we wished to determine the prevalence and the outcomes associated with hyperoxemia on day 1, sustained hyperoxemia, and excessive oxygen use in patients with early ARDS. Patients who fulfilled criteria of ARDS on day 1 and day 2 of acute hypoxemic respiratory failure were categorized based on the presence of hyperoxemia (PaO2 > 100 mmHg) on day 1, sustained (i.e., present on day 1 and day 2) hyperoxemia, or excessive oxygen use (FIO2 ≥ 0.60 during hyperoxemia).
Results
Of 2005 patients that met the inclusion criteria, 131 (6.5%) were hypoxemic (PaO2 < 55 mmHg), 607 (30%) had hyperoxemia on day 1, and 250 (12%) had sustained hyperoxemia. Excess FIO2 use occurred in 400 (66%) out of 607 patients with hyperoxemia. Excess FIO2 use decreased from day 1 to day 2 of ARDS, with most hyperoxemic patients on day 2 receiving relatively low FIO2. Multivariate analyses found no independent relationship between day 1 hyperoxemia, sustained hyperoxemia, or excess FIO2 use and adverse clinical outcomes. Mortality was 42% in patients with excess FIO2 use, compared to 39% in a propensity-matched sample of normoxemic (PaO2 55–100 mmHg) patients (P = 0.47).
Conclusions
Hyperoxemia and excess oxygen use are both prevalent in early ARDS but are most often non-sustained. No relationship was found between hyperoxemia or excessive oxygen use and patient outcome in this cohort.
Trial registration
LUNG-SAFE is registered with ClinicalTrials.gov, NCT02010073
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
ARDS
Acute respiratory distress syndrome
ICUs
Intensive care units
LUNG SAFE
Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure
ESICM
European Society of Intensive Care Medicine
PaO2
Arterial oxygen tension
FIO2
Fraction of inspired oxygen
MV
Invasive mechanical ventilation
ANOVA
Analysis of variance
LOESS
Locally estimated scatterplot smoothing
OR
Odds ratio
CI
Confidence interval
SOFA
Sepsis-related organ failure assessment
Key messages
Hyperoxemia and excess FIO2 use was prevalent in patients with early ARDS. Hyperoxemia occurred in 30% of patients, while two thirds of these patients received excess oxygen therapy.
While a similar proportion of patients were hyperoxemic on day 2 of ARDS, higher FIO2 use did decrease. Consequently, most day 2 hyperoxemia was seen in patients at lower FIO2, in whom gas exchange was improving.
In the majority of patients, both hyperoxemia and excess oxygen use were transient, although sustained hyperoxemia occurred in 12% of patients.
Higher FIO2 use was independently associated with the risk of hyperoxemia, illustrating the need for close attention to oxygen use to reduce this risk.
We found no relationship between the degree and duration of hyperoxemia or of excessive oxygen use, and outcome in early ARDS, in this patient cohort.
Background
Acute respiratory distress syndrome (ARDS) is a syndrome characterized by impaired gas exchange resulting in low oxygen tensions in the blood (i.e., hypoxemia) and tissues (i.e., hypoxia) [1]. Tissue hypoxia is harmful, leading to cell death, organ failure, and increased mortality in the critically ill [2]. While oxygen therapy can reverse tissue hypoxia, little evidence exists regarding the optimal use of oxygen in patients with ARDS. Critically ill patients frequently receive higher inspired oxygen concentrations than necessary [3], perhaps due to concerns regarding tissue hypoxia [4, 5].
Anzeige
Hyperoxemia and the resultant tissue hyperoxia may worsen systemic organ injury in the critically ill. Arterial hyperoxemia has been associated with increased mortality in some older [6‐8] but not more recent [9, 10] studies of patients with acute brain injury. Hyperoxemia was associated with worse outcomes in cohort patients with acute ischemic stroke or subarachnoid/intracerebral hemorrhage that required invasive mechanical ventilation [11]. Supplemental oxygen therapy worsened myocardial injury and infarct size in patients post myocardial infarction [12]. In patients resuscitated post cardiac arrest, hyperoxia has been associated with harm in several [13‐16] studies, although the most recent study [17] did not confirm this. Potential mechanisms of oxygen toxicity remain poorly understood and may include systemic arterial vasoconstriction [18, 19], and cytotoxic effects of reactive oxygen species [20‐22]. In randomized trials, “induced” hyperoxia (using 100% oxygen) increased 28-day mortality in septic shock patients [23], while critically ill patients randomized to a target arterial oxygen tension (PaO2) of 70–100 mmHg had lower mortality compared to patients with a “conventional” target of PaO2 up to 150 mmHg [24] in a single-center study. While a recent large international multicenter trial demonstrated no effect of conservative oxygen therapy in a diverse cohort of critically ill patients [25], a subsequent sub-study raised the possibility of clinically important harm with conservative oxygen therapy in patients with sepsis [26].
In ARDS, the relationship between oxygen use and outcome is complex. The severely impaired gas exchange means that high fraction of inspired oxygen (FIO2) use may simply reflect a more severe alveolar-arterial oxygen gradient and hence be a marker of ARDS severity. In mild ARDS, relatively modest levels of FIO2 may result in (moderate) hyperoxemia and tissue hyperoxia. In addition, severe degrees of systemic hyperoxemia (i.e., PaO2 > 300) associated with harm in other critically ill populations are not possible in ARDS. However, even moderate systemic hyperoxemia that may be more commonly seen in ARDS could be harmful [27]. Furthermore, the use of high FIO2 can have direct toxic effects on the lung [28, 29], sensitize the lung to subsequent injury, adversely affect the lung innate immune response [30], and worsen ventilation-induced injury [31‐33]. These complexities highlight the need to distinguish between hyperoxemia and high FIO2 use. In patients receiving high FIO2, it is important to determine whether this was necessary to achieve normoxemia or if it could have been avoided (i.e., excess oxygen use).
We wished to examine the impact of hyperoxemia and of excess oxygen use in this secondary analysis of patients with ARDS in the LUNG SAFE patient cohort [34]. Our primary objective was to determine the prevalence of early and sustained hyperoxemia and of excess oxygen use in patients with hyperoxemia. Secondary objectives included identifying factors associated with hyperoxemia and with excess oxygen use and examining the relationship between hyperoxemia and excess oxygen use and outcomes from ARDS.
Methods
Design, setting, and participants
This is a sub-study of the LUNG SAFE study, an international, multicenter, prospective cohort study of patients receiving invasive or noninvasive ventilation, and the detailed methods and protocol have been published elsewhere [34]. In brief, LUNG SAFE was an international, multicenter, prospective cohort study, with a 4-week enrolment window in the winter season in both hemispheres [34]. National coordinators and site investigators obtained ethics committee approval and ensured data integrity and validity.
Anzeige
Given the study focus on early hyperoxemia and excess oxygen use, we restricted the study population to patients that fulfilled ARDS criteria within 48 h of ICU admission, and who remained in the ICU for at least 2 days from ARDS onset. Patients transferred from other ICUs after 2 days, patients that developed ARDS later in their ICU stay, and patients that received early ECMO were excluded (Fig. 1). Additional methodological details are available in Additional file 1.
Fig. 1
Flow chart describing criteria used to select and to classify the ARDS study population
×
Data collection and analysis
All data were recorded for each patient at the same time each day within participating ICUs, normally as close as possible to 10 a.m. each day. Data on ventilatory settings were recorded simultaneously with arterial blood gas analysis. The following definitions were applied on day 1 and on day 2 of ARDS: hypoxemia (PaO2 < 55 mmHg), normoxemia (PaO2 55–100 mmHg), and hyperoxemia (PaO2 > 100 mmHg). Excess oxygen use was defined as the use of FIO2 ≥ 0.6 in patients with hyperoxemia (PaO2 > 100 mmHg). Patients with hyperoxemia on days 1 and 2 of ARDS were considered to have sustained hyperoxemia. Analogously, we also defined patients with sustained hypoxemia and sustained normoxemia.
The duration of invasive mechanical ventilation (MV) was calculated as the number of days between the date of intubation and the date of extubation in ICU (or death, if the patient died under invasive MV). Similarly, invasive ventilator-free days were calculated as the number of days from weaning from invasive MV to day 28, and for patients who died before weaning, we considered to have a ventilator-free-day value of 0. Patient survival was evaluated at hospital discharge, or at day 90, whichever occurred first. Our other data definitions have been previously reported [34‐37].
Statistical analyses
Descriptive statistics included proportions for categorical and mean (standard deviation) or median (interquartile range) for continuous variables. No assumptions were made for missing data. To assess differences among three groups (systemic hypoxemia, normoxemia, and hyperoxemia), we performed chi-squared test (or Fisher exact test) for discrete variables and analysis of variance (ANOVA) (or Kruskal-Wallis test) for continuous variables. Bonferroni correction was applied to determine significance in the setting of multiple comparisons. Chi-square test (or Fisher exact test), Student’s t test (or Wilcoxon Mann Whitney test) were used to assess differences between groups (i.e., sustained hyperoxemia and sustained normoxemia) in discrete and continuous distributions of parameters, respectively.
Locally estimated scatterplot smoothing (LOESS) method was used to inspect the relationship between mortality and PaO2 and FIO2 measured on day 1 and on day 2 of ARDS.
Multivariable logistic regression models were used to evaluate factors associated with the presence of either hyperoxemia or excess of oxygen use, and with mortality. In each regression model, the independent predictors (demographic characteristics and clinical parameters measured at the first day of ARDS) were identified through a stepwise regression approach. This approach combines forward and backward selection methods in an iterative procedure (with a significance level of 0.05 both for entry and retention) to select predictors in the final multivariable model. Results were reported as odds ratio (OR) with 95% confidence interval (CI).
Propensity score matching method was applied to evaluate the possible impact of sustained hyperoxemia on main outcomes (mortality, ventilation-free days, and duration of MV) in patients with mild-moderate ARDS. Patients with severe ARDS were excluded as there were no such patients in the sustained hyperoxemia group. In detail, patients with sustained hyperoxemia and sustained normoxemia were matched (1:1 match without replacement), using a caliper of 0.2 standard deviation of the logit of the propensity score, and the balance between the matched groups was assessed by the standardized differences of each independent variable used in the propensity score estimation. Statistical significance of the difference in continuous variables, as ventilation-free days and duration of MV, was evaluated with Wilcoxon signed-rank test, while for difference in proportions of deaths, we applied McNemar’s test. Survival probability in these matched groups was estimated using the Kaplan-Meier approach and assuming that patients discharged alive from hospital before 90 days were alive on day 90. Statistical difference between survival curves was assessed through Kein and Moeschberger test. The same approach was used to assess the possible impact of excess use of oxygen on main outcomes.
All p values were two-sided, with p values < 0.05 considered as statistically significant. Statistical analyses were performed with R, version 3.5.2. (R Project for Statistical Computing, http://www.R-project.org) and SAS software, version 9.4 (SAS Institute, Cary, NC, USA).
Anzeige
Results
Of 4499 patients that developed AHRF in the LUNG SAFE cohort, 2127 of these developed ARDS within 2 days of ICU admission, of whom 2052 remained in ICU for at least 2 days from ARDS onset. The study population consists of 2005 of these patients that did not receive ECMO (Fig. 1).
Systemic oxygen tensions
In the study population, 607 subjects (30%) were hyperoxemic, while 6.5% of patients remained hypoxemic, on day 1 of ARDS (Fig. 2a, Table 1, eTable 1). Density distributions of arterial oxygen tension on days 1 and 2 of ARDS (Fig. 2b) reveal similar PaO2 profiles for days 1 and 2. In the hyperoxemic population at day 1, 59% had a transient hyperoxemia, while in 250 (41%) patients, the condition was sustained, with PaO2 > 100 mmHg on both the first and second day of ARDS (Fig. 1; eTable 2). All eTables are included in Additional file 1.
Fig. 2
Arterial oxygen tensions and use of oxygen in patients on days 1 and 2 of ARDS. a The distribution of PaO2 on day 1 of ARDS, demonstrating a wide range of PaO2. b Density distributions of PaO2 on days 1 (red line) and day 2 (blue line) of ARDS. c Histogram of FIO2 and PaO2 on day 1 of ARDS. d Histogram of FIO2 and PaO2 on day 2 of ARDS. Note: in c and d, each bar is segmented into hyperoxemia (black), normoxemia (dark gray), hypoxemia (light gray), and unknown (white) component
Table 1
Characteristics of study population (n = 2005), stratified by arterial oxygenation on day 1
Parameter
Hypoxemia (PaO2 < 55 mmHg)
Normoxemia (55 mmHg ≤ PaO2 ≤ 100 mmHg)
Hyperoxemia (PaO2 > 100 mmHg)
p value (among groups)
N (%)
131 (6.53)
1267 (63.19)
607 (30.27)
Male, n (%)
73 (55.73)
796 (62.83)
359 (59.14)
0.1259
Age (years), mean ± SD
59.20 ± 16.86
62.21 ± 16.74
61.88 ± 16.82
0.1264
BMI (kg/m2), mean ± SD
27.23 ± 6.82
27.66 ± 8.26
26.90 ± 6.84
0.5646
ARDS risk factors, n (%)
None
9 (6.87)
103 (8.13)
52 (8.57)
0.8088
Only non-pulmonary
15 (11.45)
229 (18.07)
106 (17.46)
0.1641
Only pulmonary
92 (70.23)
769 (60.62)
357 (58.81)
0.0525
Both
15 (11.45)
167 (13.18)
92 (15.16)
0.3789
Illness severity at ARDS onset
PaO2 (mmHg), mean ± SD
47.1 ± 6.2
76.8 ± 11.9*
137.8 ± 41.0*†
< 0.0001
PaO2/FIO2 (mmHg), mean ± SD
75.12 ± 38.97
140.49 ± 56.70*
205.90 ± 54.88*†
< 0.0001
SpO2 (%), median (q1–q3)
88 (82–94)
95 (92–97)*
98 (97–99)*†
< 0.0001
ARDS severity, n (%)
< 0.0001
Mild
4 (3.05)
205 (16.18)*
330 (54.37)*†
< 0.0001
Moderate
22 (16.79)
683 (53.91)*
273 (33.98)*†
< 0.0001
Severe
105 (80.15)
379 (29.91)*
4 (0.66)*†
< 0.0001
PaCO2 (mmHg), mean ± SD
54.3 ± 25.0
46.3 ± 15.3*
44.8 ± 14.6*
0.0031
pH, mean ± SD
7.31 ± 0.15
7.33 ± 0.12
7.32 ± 0.13
0.7446
Bicarbonate (mmol/L), mean ± SD
26.3 ± 10.9
23.3 ± 6.5
22.3 ± 6.3*†
< 0.0001
Base excess (mEq/L), mean ± SD
0.5 ± 10.8
−2.0 ± 6.8
−3.1 ± 6.8*†
0.0001
Non-respiratory SOFA score adjusted, mean ± SD
6.14 ± 4.15
6.08 ± 3.94
6.28 ± 4.00
0.6246
SOFA score adjusted, mean ± SD
10.25 ± 4.20
9.51 ± 3.98
8.87 ± 3.93*†
0.0005
Respiration
3.79 ± 0.46
3.15 ± 0.66
2.45 ± 0.50
< 0.0001
Central nervous system
1.68 ± 1.72
1.74 ± 1.66
1.92 ± 1.69
0.1161
Cardiovascular
1.77 ± 1.74
2.03 ± 1.76
1.93 ± 1.74
0.1760
Liver
0.65 ± 0.98
0.54 ± 0.96
0.51 ± 0.92
0.2855
Coagulation
1.20 ± 1.45
0.95 ± 1.31
0.98 ± 1.34
0.1751
Renal
0.69 ± 1.04
1.77 ± 1.10
0.88 ± 1.22
0.3333
Pressor support infusion rates
Dopamine (μg/kg/min), mean ± SD
8.19 ± 6.94
8.58 ± 5.02
7.73 ± 5.98
0.4151
Dobutamine (μg/kg/min), mean ± SD
5.52 ± 3.74
5.72 ± 4.05
6.75 ± 3.53
0.3565
Noradrenaline (μg/kg/min), mean ± SD
0.50 ± 0.67
0.45 ± 0.75
0.54 ± 1.48
0.6701
Adrenaline (μg/kg/min), mean ± SD
1.10 ± 2.03
0.48 ± 0.69
0.43 ± 0.55
0.8434
Management factors at ARDS onset
Invasive mechanical ventilation, n (%)
102 (77.86)
1000 (78.93)
506 (83.36)
0.0619
Control mode of ventilation, mean ± SD
70 (54.69)
693 (55.89)
386 (64.23)†
0.0021
FIO2, median (q1–q3)
0.80 (0.50–1.00)
0.60 (0.41–0.80)*
0.65 (0.50–1.00)†
< 0.0001
FIO2 ≥ 0.6, n (%)
90 (68.70)
670 (52.88)*
400 (65.90)†
< 0.0001
FIO2 ≥ 0.6 at 2nd day, n (%)‡
64 (73.56)
372 (57.94)*
167 (43.60)*†
< 0.0001
Tidal volume (ml/kg), mean ± SD
7.9 ± 2.2
7.8 ± 2.0
7.9 ± 2.0
0.2256
PEEP (cmH2O), mean ± SD
8.7 ± 3.33
8.1 ± 3.2
7.9 ± 3.1*
0.0174
PIP (cmH2O), mean ± SD
25.7 ± 8.90
25.3 ± 8.5
25.6 ± 8.7
0.6295
Dynamic compliance (ml/cmH2O), mean ± SD
39.0 ± 38.4
36.9 ± 37.8
35.6 ± 38.9
0.7759
Total respiratory rate (breaths/min), mean ± SD
23.2 ± 7.1
21.9 ± 6.9
21.1 ± 7.0
0.0003
Standardized minute ventilation (L/min), mean ± SD
14.4 ± 7.8
11.4 ± 5.3*
10.8 ± 5.0*†
< 0.0001
Patients in whom plateau pressure measured, n (%)°
24 (18.32)
304 (23.99)
186 (30.64)
0.0012
Plateau pressure (cmH2O), mean ± SD
24.3 ± 9.0
23.4 ± 6.1
23.0 ± 5.6
0.7512
Driving pressure (cmH2O), mean ± SD
16.0 ± 8.2
14.6 ± 5.4
15.0 ± 5.2
0.4941
Clinical outcomes
Hospital mortality (90 days), n (%)
47 (35.88)
486 (38.54)
227 (37.52)
0.7934
Ventilation free days (days), median (q1–q3)
All
10.0 (0.0–22.0)
12.0 (0.0–23.0)
16.0 (0.0–24.0)†
0.0303
Survivors at ICU discharge
20.0 (14.0–24.0)
21.0 (15.0–25.0)
23.0 (18.0–26.0)*†
0.0002
Duration mechanical ventilation (days), median (q1–q3)
All
7.0 (4.0–13.0)
8.0 (4.0–15.0)
7.0 (3.0–13.0)†
0.0074
Survivors at ICU discharge
9.0 (5.0–15.0)
8.0 (4.0–14.0)
6.0 (3.0–11.0)*†
0.0002
Abbreviations: ARDS acute respiratory distress syndrome, BMI body mass index, COPD chronic obstructive pulmonary disease, FIO2 fraction of inspired oxygen, PaO2 arterial oxygen partial pressure, PaCO2 arterial carbon dioxide partial pressure, PEEP positive end-expiratory pressure, PIP peak inspiratory pressure, q1 first quartile, q3 third quartile, SOFA sepsis-related organ failure assessment, SD standard deviation, SpO2 peripheral oxygen saturation
°Plateau pressure and driving pressure values are limited to patients in whom this value was reported and in whom either an assist control mode was used or in whom a mode permitting spontaneous ventilation was used and where the set and total respiratory rates were equal. Patients receiving HFOV or ECMO were also excluded
‡Percentage was calculated on patients with FIO2 available during the second day and with FIO2 ≥ 0.60 at day 1
*p value < 0.05 (Bonferroni’s correction), comparison with “Hypoxemia” group
†p value < 0.05 (Bonferroni’s correction), comparison with “Normoxemia” group
×
A multivariable analysis of factors independently associated with day 1 hyperoxemia identified higher FIO2 use, lower PEEP, lower respiratory rate, a lower sepsis-related organ failure assessment (SOFA) cardiovascular score, and comorbidities such as neoplasm and/or immunosuppression and heart failure (Table 2).
Table 2
Factors associated with day 1 hyperoxemia (PaO2 > 100 mmHg) and with excess oxygen use (FIO2 ≥ 0.6 in patients with PaO2 > 100 mmHg) in the study population
Parameter
Odds ratio (95% confidence interval)
p value
Outcome—hyperoxemia at day 1 (model* on 1855 patients)
FIO2 (0.1 unit)
1.168 (1.115; 1.224)
< .0001
Bicarbonate (mmol/L)
0.967 (0.951; 0.984)
< .0001
Total respiratory rate (breath/min)
0.971 (0.956; 0.986)
0.0002
PEEP (cmH2O)
0.944 (0.910; 0.979)
0.0017
Active/hematologic neoplasm or immunosuppression (ref. no.)
1.414 (1.111; 1.801)
0.0050
SOFA score – Cardiovascular
0.925 (0.870; 0.984)
0.0139
Heart failure (ref. no.)
1.482 (1.080; 2.033)
0.0148
Outcome—excess oxygen use at day 1 (model°on 1694 patients)
PaO2/FIO2 (mmHg)
0.978 (0.976; 0.980)
< .0001
PEEP (cmH2O)
1.144 (1.091; 1.199)
< .0001
PIP (cmH2O)
1.029 (1.014; 1.045)
0.0002
Bicarbonate (mmol/L)
0.971 (0.954; 0.989)
0.0013
Age (years)
0.988 (0.981; 0.996)
0.0023
BMI (kg/m2)
0.980 (0.965; 0.995)
0.0111
Tidal volume (ml/kg IBW)
1.081 (1.017; 1.149)
0.0122
Abbreviations: BMI body mass index, FIO2 fraction of inspired oxygen, PEEP positive end-expiratory pressure, PIP peak inspiratory pressure, SOFA sepsis-related organ failure, PaO2 arterial oxygen partial pressure, IBW ideal body weight
*Multivariable logistic model with presence of hyperoxemia (PaO2 > 100 mmHg) as dependent dichotomous variable and the predictors were identified by stepwise approach. One hundred and fifty patients were excluded due to missing values for the response or explanatory variables. List of possible predictors in stepwise approach: age, sex, body mass index, comorbidities (presence of heart failure, diabetes mellitus chronic renal failure, chronic obstructive pulmonary disease or home ventilation, active neoplasm of hematologic neoplasm or immunosuppression), ARDS risk factors (none, only non-pulmonary, only pulmonary, both types), bicarbonates concentration, management factors (presence of invasive mechanical ventilation, tidal volume, PEEP, PIP, total respiratory rate, minute ventilation), and FIO2 and SOFA components (CNS, cardiovascular, renal, liver, coagulation score)
°Multivariable logistic model with excess of oxygen use (FIO2 ≥ 0.6 and PaO2 > 100 mmHg) as dependent dichotomous variable and predictors identified by stepwise approach. Three hundred and eleven observations were deleted due to missing values for the response or explanatory variables
List of possible predictors in stepwise approach: age, sex, body mass index, comorbidities (presence of heart failure, diabetes mellitus chronic renal failure, chronic obstructive pulmonary disease or home ventilation, active neoplasm of hematologic neoplasm or immunosuppression), ARDS risk factors (none, only non-pulmonary, only pulmonary, both types), bicarbonates concentration, management factors (presence of invasive mechanical ventilation, tidal volume, PEEP, PIP, total respiratory rate, minute ventilation), and PaO2/FIO2 ratio and non-respiratory SOFA components (CNS, cardiovascular, renal, liver, coagulation score)
Use of oxygen
FIO2 use varied widely across the spectrum of PaO2 on day 1 of ARDS (Fig. 2c). In patients that received a FIO2 greater than 0.9 (459 patients), 11% had systemic hypoxemia, while 38% had hyperoxemia (Fig. 2c). Median PaO2 was similar across deciles of FIO2 (Fig. 3a). On day 2 of ARDS, the proportions of patients receiving higher FIO2 decreased, although around one third of patients were hyperoxemic at each decile of FIO2 (Figs. 2d and 3b, c). In contrast, 40% (57/131) of patients with hypoxemia on day 1 received a FIO2 of 0.5 or less. Median FIO2 decreased between day 1 and day 2 in patients with hyperoxemia, normoxemia, and hypoxemia (Fig. 3b), although median PaO2 remained similar across deciles of FIO2 on day 2 (Fig. 3c).
Fig. 3
Use of inspired oxygen in patients on days 1 and 2 of ARDS. a A box plot of PaO2 at each decile of FIO2 uses on day 1 of ARDS. b A box plot of FIO2 used on day 1 and 2 of ARDS in the study population classified by PaO2 on day 2 (hypoxemia, normoxemia, hyperoxemia, and unknown). c A box plot of PaO2 at each decile of FIO2 used on day 2 of ARDS
×
Anzeige
Excess oxygen use was seen in 400 patients, comprising 66% of all patients with hyperoxemia, on day 1 of ARDS (Table 1). In 315 patients (79%), excess oxygen use was transient, while in 85 (21%) patients, excess oxygen use was also seen on day 2 of ARDS. In multivariable analysis, factors independently associated with excess oxygen use included lower PaO2/FIO2 ratio, higher PEEP, higher tidal volume, and chronic renal failure (Table 2).
Hyperoxemia, excess oxygen use, and outcome
On day 1, LOESS demonstrated the relationship between unadjusted mortality risk and PaO2 was relatively flat over the range of PaO2 (Fig. 4a). On day 2, the unadjusted risk of hospital mortality increased in patients with systemic hypoxemia (Fig. 4b). LOESS in non-hypoxemic patients demonstrated that unadjusted mortality risk increased with increasing FIO2 on both days 1 and 2 (Fig. 4c, d).
Fig. 4
Relationship between oxygen and outcome in patients with ARDS. a A locally estimated scatterplot smoothing (LOESS) of the relationship between PaO2 on day 1 of ARDS and mortality risk. b A LOESS of the relationship between PaO2 use on day 2 of ARDS and mortality risk. c A LOESS of the relationship between FIO2 use on day 1 in non-hypoxemic patients with ARDS and mortality risk. d A LOESS of the relationship between FIO2 use on day 2 in non-hypoxemic patients with ARDS and mortality risk. Note: LOESS uses a bandwidth 2/3 and 1 degree of polynomial regression
×
Multivariate analyses found no independent association between day 1 systemic oxygen tension or inspired oxygen concentration and outcome, in either the full study population or in the subset of patients with hyperoxemia (Table 3).
Table 3
Factors associated with hospital mortality in study population (n = 2005) and in patients with hyperoxemia at day 1 (n = 607)
Factor
Odds ratio (95% confidence interval)
p value
Study population (n= 2005)—model on 1360 patients
Age (year)
1.022 (1.015; 1.030)
<.0001
BMI (kg/m2)
0.978 (0.962; 0.995)
0.0098
SOFA score—cardiovascular
1.182 (1.096; 1.275)
<.0001
SOFA score—respiratory
1.405 (1.182; 1.669)
0.0001
SOFA score—renal
1.209 (1.087; 1.344)
0.0005
SOFA score—central nervous system
1.147 (1.061; 1.240)
0.0006
Active/hematologic neoplasm or immunosuppression (ref. no.)
2.248 (1.697; 2.978)
<.0001
Chronic liver failure (ref. no.)
4.315 (2.184; 8.523)
<.0001
PIP (cmH2O)
1.030 (1.013; 1.046)
0.0003
Invasive mechanical ventilation (ref. no.)
0.497 (0.339; 0.729)
0.0004
Bicarbonate (mmol/L)
0.979 (0.960; 0.997)
0.0240
Patients with PaO2> 100 mmHg (n= 607)—model on 530 patients
Age (year)
1.031 (1.018; 1.044)
<.0001
SOFA score —renal
1.362 (1.152; 1.610)
0.0003
SOFA score—cardiovascular
1.205 (1.073; 1.352)
0.0016
Active/hematologic neoplasm or immunosuppression (ref. no)
1.828 (1.186; 2.819)
0.0063
Chronic liver failure (ref. no.)
4.091 (1.256; 13.328)
0.0194
Total respiratory rate (breath/min)
1.043 (1.015; 1.072)
0.0027
Bicarbonate (mmol/L)
0.958 (0.924; 0.994)
0.0210
Abbreviations: BMI body mass index, PIP peak inspiratory pressure, SOFA sepsis-related organ failure assessment
In a propensity-matched analysis (n = 448), no outcome differences were found in patients with sustained hyperoxemia compared to matched sustained normoxemia patients (Fig. 5a; eTable 3). Similarly, mortality in patients with hyperoxemia and excess oxygen use (42%) was not different to that in patients with normoxemia (39%, P = 0.47) in a propensity-matched sample (n = 666) (Fig. 5b; eTable 4).
Fig. 5
Kaplan-Meier curves for hospital survival in matched samples. a Survival probability in matched sample (n = 448) of patients with sustained normoxemia and with sustained hyperoxemia. b Survival probability in matched sample (n = 646) of patients with normoxemia and with excess oxygen use at day 1. Notes: (1) Normoxemia is defined as 55 mmHg ≤ PaO2 ≤ 100 mmHg on day 1 of ARDS, sustained normoxemia defined as normoxemia on day 1 and 2 of ARDS, sustained hyperoxemia defined as PaO2 > 100 mmHg on day 1 and 2 of ARDS, and excess oxygen use defined as PaO2 > 100 mmHg and FIO2 ≥ 0.60 on day 1 of ARDS. (2) Mortality is defined as mortality at hospital discharge or at 90 days, whichever event occurred first. We assumed that patients discharged alive from the hospital before 90 days were alive on day 90. (3) The number of patients at risk reported at the bottom of the figure is referred to as the end of the corresponding day
×
Anzeige
Discussion
Our findings demonstrate that hyperoxemia and excess FIO2 use was prevalent in patients with early ARDS in patients enrolled in the LUNG SAFE cohort. Hyperoxemia occurred in 30% of patients, while two thirds of these patients received excess oxygen therapy. While a similar proportion of patients was hyperoxemic on day 2 of ARDS, higher FIO2 use did decrease. Consequently, most day 2 hyperoxemia was seen in patients at lower FIO2, in whom gas exchange was improving. In the majority of patients, both hyperoxemia and excess oxygen use were transient, although sustained hyperoxemia occurred in 12% of patients. Higher FIO2 use was independently associated with the risk of hyperoxemia, illustrating the need for close attention to oxygen use to reduce this risk. We found no relationship between the degree and duration of hyperoxemia or of excessive oxygen use, and outcome in early ARDS, in this patient cohort.
Oxygen use in ARDS
The optimal use of oxygen in patients with ARDS remains unclear. While guidelines recommend the use of supplemental oxygen during acute hypoxemia [38], specific therapeutic goals in terms of PaO2 or SpO2 are lacking. The ARDS Network targeted a PaO2 of 55–80 mmHg in the ARMA trial of patients with ARDS [39]. The British Thoracic Society suggested a target SpO2 of 94–98% in acutely ill patients who are not at risk of hypercapnic respiratory failure (only Grade D recommendation) [40, 41].
Tissue hypoxia directly causes cellular death, leading to organ failure and increased mortality in ICU patients. In contrast, high oxygen concentrations may be directly toxic to the lung via mechanisms that remain poorly characterized but may include alveolar-capillary “leak” and fibrogenesis [42, 43], arterial vasoconstriction [18, 19], and the production of reactive oxygen species with consequent proinflammatory and cytotoxic effects [20‐22]. Consequently, clinicians are faced with the task of titrating the amount of oxygen delivered to avoid both hypoxemia and hyperoxemia. Prior studies show that clinicians appear to use higher FIO2 than is necessary in the critically ill [3]. While the reasons are unclear, potential explanations include concerns over the need to avoid tissue hypoxia, [4, 5] a desire to provide a “buffer” should a clinical deterioration occur, or because the consequences of hyperoxia are considered less severe than hypoxia.
Hyperoxemia in ARDS
In this study, hyperoxemia was seen on day 1 in a third of ARDS patients enrolled in the LUNG SAFE study. The fact that hyperoxemia was more prevalent than hypoxemia in patients immediately following the onset of ARDS, might seem surprising given that ARDS is a syndrome defined by impaired gas exchange but presumably reflects the effectiveness of ventilatory support and oxygen therapy. Of interest, hyperoxemia was associated with lower SOFA cardiovascular scores, suggesting that clinicians were not permitting hyperoxemia as a “buffer” in patients with shock. In this patient cohort, hyperoxemia was relatively transient in the majority of patients in early ARDS.
A minority of patients had sustained hyperoxemia in this cohort. Interestingly, day 2 median FIO2 was the same in patients with sustained hyperoxemia and normoxemia, while P/F ratio was substantially higher in the hyperoxemic patients. These findings suggest that sustained hyperoxemia in these patients is a function of rapidly improving gas exchange rather than excess oxygen use. Sustained hyperoxemia did not have a demonstrable impact on patient mortality. In the matched propensity score analysis, outcomes in patients with sustained hyperoxemia were comparable to that seen in normoxemic patients.
These findings contrast with prior findings regarding hyperoxemia in other critically ill cohorts. However, an important difference between these studies and the current study relates to the severity of hyperoxemia. De Jonge and colleagues reported an association between early hyperoxemia and outcome in patients with acute respiratory failure in the Netherlands [44]. However, this association was only seen in patients with relatively severe hyperoxemia (PaO2 > 123 mmHg; uncommon in our cohort) and only on day 1 of ICU admission, while there was no adverse association between hyperoxia over the entire ICU stay and patient outcome. The potential for harm from hyperoxia in the critically ill appears to be enhanced with greater severity and “dose” of hyperoxemia [45]. In fact, in critically ill patient groups where lung function was relatively preserved, such as patients post cardiac arrest, harm was mainly associated with systemic oxygen tensions over 300 mmHg [13]. Greater degrees of hyperoxemia were likely in both the study by Girardis et al. [24] and in the HYPERS2S trial [23] of “induced” systemic hyperoxemia in patients with sepsis. Our study was focused solely on patients with ARDS, where due to their impaired gas exchange, they cannot attain this severity of systemic hyperoxia.
Oxygen use in ARDS
High inspired oxygen use was frequent in patients on day 1 of ARDS, with two thirds of patients with systemic hyperoxia receiving at least 60% oxygen in day 1—which we termed “excess oxygen use” on the basis that these patients could safely have had their FIO2 reduced while maintaining normoxemia. Of importance, high FIO2 use was frequently transient, with a marked decrease in higher inspired oxygen concentration use on day 2. Nevertheless, at each decile of FIO2, approximately one third of patients were hyperoxemic, suggesting the potential existed to further reduce oxygen use. Of interest, there was an association between excess oxygen use and the use of higher tidal volumes.
Our unadjusted analyses suggested an association between higher FIO2 and poorer outcome. However, in multivariate analyses, which accounted for lung injury severity, we found no independent association between high FIO2 use and patient outcome. Propensity-matched analyses in patients excess FIO2 confirmed no difference in mortality compared to normoxemic patients.
Our findings do not support prior concerns [24] raised regarding the use of higher FIO2 in patients with ARDS that are not hypoxemic. This finding also contrasts with the analysis of patients in the ARDS Network trials that found that the cumulative duration of “above target” oxygen exposure (FIO2 above 0.5 in ARDS patients while PaO2 was > 80 mmHg) was associated with mortality [27]. While the reasons for the divergent findings are unclear, potential explanations include the fact that our analysis concentrated on early ARDS, the fact that high FIO2 use was transient in most patients in our cohort, and the fact that this analysis may have been better adjusted for the impact of lung injury severity.
Limitations
This study has several limitations. The non-linearity of P/F ratio at different FIO2 [46] makes it difficult to predict the effect of FIO2 on PaO2/FIO2, especially when matching patients with mild ARDS. While we have adjusted our analyses to account for known measured confounders, the possibility remains that some of our findings may arise from unmeasured or residual confounding. Moreover, we cannot make causal inferences for any associations seen, given the observational nature of our study. Our dataset comprises daily arterial blood gas and FIO2 data, taken at a standardized time each morning. It is possible that these data do not properly reflect the spectrum of FIO2 use and PaO2 data over the course of that day. Given this, in the hyperoxemia analyses, we focused on patients that were hyperoxemic on both days 1 and 2 of ARDS. There are no single accepted definitions for hyperoxemia, hypoxemia, or excess oxygen use, so our definitions are of necessity arbitrary, and other definitions have been used in other analyses. This could partly explain any divergence in findings across these studies. Lastly, our assumption that inpatients at day 90 survived to hospital discharge is a further limitation.
Conclusions
Our findings demonstrate that hyperoxemia and high fractional inspired oxygen use is prevalent in patients with early ARDS in patients enrolled in the LUNG SAFE cohort. Higher FIO2 use decreased from day 1 to day 2 of ARDS, with most day 2 hyperoxemia seen in patients at lower FIO2, in whom gas exchange was improving. Reassuringly, we found no relationship between hyperoxemia or excessive oxygen use and patient outcome in this cohort.
We wish to acknowledge the help of Guy Francois of the European Society of Intensive Care Medicine, Brussels, Belgium, for his assistance with the study.
LUNG SAFE Steering Committee: Antonio Pesenti, John G. Laffey, Laurent Brochard, Andres Esteban, Luciano Gattinoni, Frank van Haren, Anders Larsson, Daniel F. McAuley, Marco Ranieri, Gordon Rubenfeld, B. Taylor Thompson, Hermann Wrigge, Arthur S. Slutsky.
LUNG SAFE National Coordinators: Argentina: Fernando Rios; Australia/New Zealand: Frank Van Haren; Belgium: Sottiaux T, Depuydt P; Bolivia: Fredy S Lora; Brazil: Luciano Cesar Azevedo; Canada: Eddy Fan; Chile: Guillermo Bugedo; China: Haibo Qiu; Colombia: Marcos Gonzalez; Costa Rica: Juan Silesky; Czech Republic: Vladimir Cerny; Denmark: Jonas Nielsen; Ecuador: Manuel Jibaja; France: Tài Pham; Germany: Hermann Wrigge; Greece: Dimitrios Matamis; Guatemala: Jorge Luis Ranero; India: Pravin Amin; Iran: S.M. Hashemian; Ireland: Kevin Clarkson; Italy: Giacomo Bellani; Japan: Kiyoyasu Kurahashi; Mexico: Asisclo Villagomez; Morocco: Amine Ali Zeggwagh; Netherlands: Leo M Heunks; Norway: Jon Henrik Laake; Philippines: Jose Emmanuel Palo; Portugal: Antero do Vale Fernandes; Romania: Dorel Sandesc; Saudi Arabia: Yaasen Arabi; Serbia: Vesna Bumbasierevic; Spain: Nicolas Nin, Jose A Lorente; Sweden: Anders Larsson; Switzerland: Lise Piquilloud; Tunisia: Fekri Abroug; UK: Daniel F McAuley, Lia McNamee; Uruguay: Javier Hurtado; USA: Ed Bajwa; Venezuela: Gabriel Démpaire
LUNG SAFE Site Investigators (by Country):
Albania: Uhc Mother Theresa (Tirana): Hektor Sula, Lordian Nunci; University Hospital Shefqet Ndroqi (Tirana): Alma Cani
Argentina: Clinica De Especialidades (Villa Maria): Alan Zazu; Hospital Dr Julio C. Perrando (Resistencia): Christian Dellera, Carolina S Insaurralde; Sanatorio Las Lomas (San Isidro, Buenos Aires): Risso V Alejandro; Sanatorio De La Trinidad San Isidro (San Isidro): Julio Daldin, Mauricio Vinzio; Hospital Español De Mendoza (Godoy Cruz - Mendoza): Ruben O Fernandez; Hospital Del Centenario (Rosario): Luis P Cardonnet, Lisandro R Bettini; San Antonio (Gualeguay (Entre Rios)): Mariano Carboni Bisso, Emilio M Osman; Cemic (Buenos Aires): Mariano G Setten, Pablo Lovazzano; Hospital Universitrario Austral (Pilar): Javier Alvarez, Veronica Villar; Hospital Por + Salud (Pami) Dr. Cesar Milstein (Buenos Aires): Norberto C Pozo, Nicolas Grubissich; Sanatorio Anchorena (Buenos Aires): Gustavo A Plotnikow, Daniela N Vasquez; Sanatorio De La Trinidad Mitre (Buenos Aires): Santiago Ilutovich, Norberto Tiribelli; Hospital Luis Lagomaggiore (Mendoza): Ariel Chena, Carlos A Pellegrini; H.I.G.A San Martín (La Plata): María G Saenz, Elisa Estenssoro; Hospital Misericordia (Cordoba): Matias Brizuela, Hernan Gianinetto; Sanatorio Juncal (Temperley): Pablo E Gomez, Valeria I Cerrato; Hospital D. F. Santojanni (Buenos Aires): Marco G Bezzi, Silvina A Borello; Hospital Alejandro Posadas (Buenos Aires): Flavia A Loiacono, Adriana M Fernandez
Australia: St. Vincent’s Hospital, Sydney (Darlinghurst): Serena Knowles, Claire Reynolds; St George Public Hospital (Kogarah): Deborah M Inskip, Jennene J Miller; Westmead Hospital (Westmead): Jing Kong, Christina Whitehead; Flinders Medical Centre (Bedford Park, South Australia): Shailesh Bihari; John Hunter Hospital (Newcastle): Aylin Seven, Amanda Krstevski; Canberra Hospital (Garran): Helen J Rodgers, Rebecca T Millar; Calvary Mater Newcastle (Waratah): Toni E Mckenna, Irene M Bailey; Cabrini Hospital (Melbourne): Gabrielle C Hanlon; Liverpool Hospital (Liverpool): Anders Aneman, Joan M Lynch; Coffs Harbour Health Campus (Coffs Harbour): Raman Azad, John Neal; Sir Charles Gairdner Hospital (Nedlands): Paul W Woods, Brigit L Roberts; Concord Hospital (Concord): Mark R Kol, Helen S Wong
Austria: General Hospital Of Vienna/Medical University Of Vienna (Vienna): Katharina C Riss, Thomas Staudinger
Belgium: Cliniques universitaires St Luc, UCL (Brussels): Xavier Wittebole, Caroline Berghe; CHU Dinant-Godinne (Yvoir): Pierre A Bulpa, Alain M Dive; AZ Sint Augustinus Veurne (Veurne): Rik Verstraete, Herve Lebbinck; Ghent University Hospital (Ghent): Pieter Depuydt, Joris Vermassen; University Hospitals Leuven (Leuven): Philippe, Meersseman, Helga Ceunen
Brazil: Hospital Renascentista (Pouso Alegre): Jonas I Rosa, Daniel O Beraldo; Vitoria Apart Hospital (Serra): Claudio Piras, Adenilton M Rampinelli; Hospital Das Clinicas (São Paulo): Antonio P Nassar Jr; Hospital Geral Do Grajaù (São Paulo): Sergio Mataloun, Marcelo Moock; Evangelical Hospital (Cachoeiro De Itapemirim/Espírito Santo): Marlus M Thompson, Claudio H Gonçalves; Hospital Moinhos De Vento (Porto Alegre): Ana Carolina P Antônio, Aline Ascoli; Hospital Alvorada Taguatinga (Taguatinga): Rodrigo S Biondi, Danielle C Fontenele; Complexo Hospitalar Mngabeira Tarcisio Burity (Joao Pessoa): Danielle Nobrega, Vanessa M Sales
Brunei Darussalam: Raja Isteri Pengiran Anak Saleha (Ripas) Hospital (Bandar Seri Begawan): Dr. Suresh Shindhe, Dr. Dk Maizatul Aiman B Pg Hj Ismail
Canada: Medical-Surgical ICU of St Michael’s Hospital (Toronto): John Laffey, Francois Beloncle; St. Josephs Health Centre (Toronto): Kyle G Davies, Rob Cirone; Sunnybrook Health Sciences Center (Toronto): Venika Manoharan, Mehvish Ismail; Toronto Western Hospital (Toronto): Ewan C Goligher, Mandeep Jassal; Medical Surgical ICU of the Toronto General Hospital (Toronto): Erin Nishikawa, Areej Javeed; Cardiovascular ICU of St Michael’s Hospital (Toronto): Gerard Curley, Nuttapol Rittayamai; Cardiovascular ICU of the Toronto General Hospital (Toronto): Matteo Parotto, Niall D Ferguson; Mount Sinai Hospital (Toronto): Sangeeta Mehta, Jenny Knoll; Trauma-Neuro ICU of St Michael’s Hospital (Toronto): Antoine Pronovost, Sergio Canestrini
Chile: Hospital Clínico Pontificia Universidad Católica De Chile (Santiago): Alejandro R Bruhn, Patricio H Garcia; Hospital Militar De Santiago (Santiago): Felipe A Aliaga, Pamela A Farías; Clinica Davila (Santiago): Jacob S Yumha; Hospital Guillermo Grant Benavente (Concepcion): Claudia A Ortiz, Javier E Salas; Clinica Las Lilas (Santiago): Alejandro A Saez, Luis D Vega; Hospital Naval Almirante Nef (Viña Del Mar): Eduardo F Labarca, Felipe T Martinez; Hospital Luis Tisné Brousse (Penanolen): Nicolás G Carreño, Pilar Lora
China: The Second Affiliated Hospital Of Harbin Medical University (Harbin): Haitao Liu; Nanjing Zhong-Da Hospital, Southeast University (Nanjing): Haibo Qiu, Ling Liu; The First Affiliated Hospital Of Anhui Medical University (Hefei): Rui Tang, Xiaoming Luo; Peking University People’s Hospital (Beijing): Youzhong An, Huiying Zhao; Fourth Affiliated Hospital Of Harbin Medical University (Harbin): Yan Gao, Zhe Zhai; Nanjing Jiangbei Peoples Hospital Affiliated To Medical School Of Southeast University (Nanjing): Zheng L Ye, Wei Wang; The First Affiliated Hospital Of Dalian Medical University (Dalian): Wenwen Li, Qingdong Li; Subei Peoples Hospital Of Jiangsu Province (Yanghzou): Ruiqiang Zheng; Jinling Hospital (Nanjing): Wenkui Yu, Juanhong Shen; Urumqi General Hospital (Urumqi): Xinyu Li; Intensive Care Unit, First Affiliated Hospital Of Wanna Medical College, Yijishan Hospital, (Wuhu): Tao Yu, Weihua Lu; Sichuan Provincial Peoples Hospital (Chengdu): Ya Q Wu, Xiao B Huang; Hainan Province Peoples Hospital (Haikou): Zhenyang He; Peoples Hospital Of Jiangxi Province (Nanchang): Yuanhua Lu; Qilu Hospital Of Shandong University (Jinan): Hui Han, Fan Zhang; Zhejiang Provincial Peoples Hospital (Hangzhou): Renhua Sun; The First Affiliated Hospital Of Bengbu Medical College (Bengbu, Anhui): Hua X Wang, Shu H Qin; Nanjing Municipal Government Hospital (Nanjing): Bao H Zhu, Jun Zhao; The First Hospital Of Lanzhou University (Lanzhou): Jian Liu, Bin Li; The First Affiliated Hospital Of Chongqing University Of Medical Science (Chongqing): Jing L Liu, Fa C Zhou; Xuzhou Central Hospital, Jiangsu Province, China (Xuzhou): Qiong J Li, Xing Y Zhang; The First Peoples Hospital Of Foshan (Foshan): Zhou Li-Xin, Qiang Xin-Hua; The First Affiliated Hospital Of Guangxi Medical University (Nanning): Liangyan Jiang; Renji Hospital, Shanghai Jiao Tong University School Of Medicine (Shanghai): Yuan N Gao, Xian Y Zhao; First Hospital Of Shanxi Medical University (Taiyuan): Yuan Y Li, Xiao L Li; Shandong Provincial Hospital (Jinan): Chunting Wang, Qingchun Yao; Fujian Provincial Hospital (Fuzhou): Rongguo Yu, Kai Chen; Henan Provincial People’s Hospital (Zhengzhou): Huanzhang Shao, Bingyu Qin; The Second Affiliated Hospital Of Kunming Medical University (Kunming City): Qing Q Huang, Wei H Zhu; Xiangya Hospital, Central South University (Changsha): Ai Y Hang, Ma X Hua; The First Affiliated Hospital Of Guangzhou Medical University (Guangzhou): Yimin Li, Yonghao Xu; Peoples Hospital of Hebei Province (Shijiazhuang): Yu D Di, Long L Ling; Guangdong General Hospital (Guangzhou): Tie H Qin, Shou H Wang; Beijing Tongren Hospital (Beijing): Junping Qin; Jiangsu Province Hospital (Nanjing): Yi Han, Suming Zhou
Colombia: Fundación Valle Del Lili (Cali): Monica P Vargas
Costa Rica: Hospital San Juan De Dios (San José): Juan I Silesky Jimenez, Manuel A González Rojas; Hospital San Juan De Dios (San José): Jaime E Solis-Quesada, Christian M Ramirez-Alfaro
Czech Republic: University Hospital Of Ostrava (Ostrava): Jan Máca, Peter Sklienka
Denmark: Aarhus Universitetshospital (Aarhus N): Jakob Gjedsted, Aage Christiansen; Rigshopitalet: Jonas Nielsen
Ecuador: Hospital Militar (Quito): Boris G Villamagua, Miguel Llano
France: Clinique du Millenaire (Montpellier): Philippe Burtin, Gautier Buzancais; Centre Hospitalier (Roanne): Pascal Beuret, Nicolas Pelletier; CHU d’Angers (Angers): Satar Mortaza, Alain Mercat; Hôpital Marc Jacquet (Melun): Jonathan Chelly, Sébastien Jochmans; CHU Caen (Caen): Nicolas Terzi, Cédric Daubin; Henri Mondor Hospital (Créteil): Guillaume Carteaux, Nicolas de Prost; Cochin Hospital (Paris): Jean-Daniel Chiche, Fabrice Daviaud; Hôpital Tenon (Paris): Tai Pham, Muriel Fartoukh; CH Mulhouse-Emile Muller (Mulhouse): Guillaume Barberet, Jerome Biehler; Archet 1 University Hospital (Nice): Jean Dellamonica, Denis Doyen; Hopital Sainte Musse (Toulon): Jean-Michel Arnal, Anais Briquet; Hopital Nord - Réanimation des Détresses Respiratoires et Infections Sévères (Marseille): Sami Hraiech, Laurent Papazian; HEGP (Paris):Arnaud Follin; Louis Mourier Hospital (Colombes): Damien Roux, Jonathan Messika; Centre Hospitalier de Dax (Dax): Evangelos Kalaitzis; Réanimation Médicale, GH Pitié-Salpêtrière (Paris): Laurence Dangers, Alain Combes; Ap-Hp Ambroise Paré (Boulogne-Billancourt): Siu-Ming Au; University Hospital Rouen (Rouen): Gaetan Béduneau, Dorothée Carpentier; CHU Amiens (Amiens - Salouel): Elie H Zogheib, Herve Dupont; Centre Hospitalier Intercommunal Robert Ballanger (Aulnay Sous Bois): Sylvie Ricome, Francesco L Santoli; Centre Hospitalier René Dubos (Pontoise): Sebastien L Besset; CHI Portes de l’Oise (Beaumont Sur Oise): Philippe Michel, Bruno Gelée; Archet 2 University Hospital (Nice): Pierre-Eric Danin, Bernard Goubaux; Centre Hospitalier Pierre Oudot (Bourgoin Jallieu): Philippe J Crova, Nga T Phan; CH Dunkerque (Dunkerque): Frantz Berkelmans; Centre Hospitalier de Belfort Montbéliard (Belfort): Julio C Badie, Romain Tapponnier; Centre Hospitalier Emile Muller (Mulhouse): Josette Gally, Samy Khebbeb; Hôpital de Hautepierre-Hôpitaux Universitaires de Strasbourg (Strasbourg): Jean-Etienne Herbrecht, Francis Schneider; Centre Hospitalier de Dieppe (Dieppe): Pierre-Louis M Declercq, Jean-Philippe Rigaud; Bicetre (Le Kremin-Bicetre): Jacques Duranteau, Anatole Harrois; CHU Gabriel Montpied (Clermont-Ferrand): Russell Chabanne, Julien Marin; CHU Estaing (Clermont-Ferrand): Charlene Bigot, Sandrine Thibault; CHI Eure-Seine Evreux (Evreux): Mohammed Ghazi, Messabi Boukhazna; Centre Hospitalier d Châlons en Champagne (Châlons en Champagne): Salem Ould Zein; CH Beauvais (Beauvais): Jack R Richecoeur, Daniele M Combaux; Centre Hospitalier Le Mans (Le Mans): Fabien Grelon, Charlene Le Moal; Hôpital Fleyriat (Bourg en Bresse): Elise P Sauvadet, Adrien Robine; Hôpital Saint Louis (Paris): Virginie Lemiale, Danielle Reuter; Service de Pneumologie Pitié-Salpétrière (Paris): Martin Dres, Alexandre Demoule; Centre Hospitalier Gonesse (Gonesse): Dany Goldgran-Toledano; Hôpital Croix Rousse (Lyon): Loredana Baboi, Claude Guérin
Germany: St. Nikolaus-Stiftshospital (Andernach): Ralph Lohner; Fachkrankenhaus Coswig Gmbh (Coswig):Jens Kraßler, Susanne Schäfer; University Hospital Frankfurt (Frankfurt am Main): Kai D Zacharowski, Patrick Meybohm; Department of Anaesthesia & Intensive Care Medicine, University Hospital of Leipzig (Leipzig): Andreas W Reske, Philipp Simon; Asklepios Klinik Langen (Langen): Hans-Bernd F Hopf, Michael Schuetz; Städtisches Krankenhaus Heinsberg (Heinsberg): Thomas Baltus
Greece: Hippokrateion General Hospital Of Athens (Athens): Metaxia N Papanikolaou, Theonymfi G Papavasilopoulou; Gh Ahepa (Thessaloniki): Giannis A Zacharas, Vasilis Ourailogloy; Hippokration General Hospital of Thessaloniki (Thessaloniki): Eleni K Mouloudi, Eleni V Massa; Hospital General of Kavala (Kavala): Eva O Nagy, Electra E Stamou; Papageorgiou General Hospital (Thessaloniki): Ellada V Kiourtzieva, Marina A Oikonomou
Guatemala: Hospital General De Enfermedades, Instituto Guatemalteco De Seguridad Social (Ciudad De Guatemala): Luis E Avila; Centro Médico Militar (Guatemala): Cesar A Cortez, Johanna E Citalán
India: Deenanath Mangeshkar Hospital And Research Center (Pune): Sameer A Jog, Safal D Sable; Care Institute Of Medical Sciences (CIMS) Hospital (Ahmedabad): Bhagyesh Shah; Sanjay Gandhi Postgraduate Institute Of Medical Sciences (SGPGIMS) (Lucknow): Mohan Gurjar, Arvind K Baronia; Rajasthan Hospital (Ahmedabad): Mohammedfaruk Memon; National Institute Of Mental Health And Neuro Sciences (NIMHANS) (Bangalore): Radhakrishnan Muthuchellappan, Venkatapura J Ramesh; Anaesthesiology Unit of the Kasturba Medical College & Dept of Respiratory Therapy, SHOAS, Manipal University (Manipal): Anitha Shenoy, Ramesh Unnikrishnan; Sanjeevan Hospital (Pune): Subhal B Dixit, Rachana V Rhayakar; Apollo Hospitals (Chennai): Nagarajan Ramakrishnan, Vallish K Bhardwaj; Medicine Unit of the Kasturba Medical College & Dept of Respiratory Therapy, SHOAS, Manipal University (Manipal): Heera L Mahto, Sudha V Sagar; G Kuppuswamy Naidu Memorial Hospital (Coimbatore): Vijayanand Palaniswamy, Deeban Ganesan
Ireland: St Vincent’s University Hospital (Dublin): Edel A Meaney, Alistair Nichol; Mercy University Hospital (Cork): Karl M Knapman, Donall O’Croinin; Cork University Hospital (Cork): Eimhin S Dunne, Dorothy M Breen; Galway University Hospital (Galway): Kevin P Clarkson, Rola F Jaafar; Beaumont Hospital (Dublin): Rory Dwyer, Fahd Amir; Mater Misericordiae University Hospital (Dublin): Olaitan O Ajetunmobi, Aogan C O’Muircheartaigh; Tallaght Hospital (Dublin): Colin S Black, Nuala Treanor; Saint James’s Hospital (Dublin): Daniel V Collins, Wahid Altaf
Italy: Santa Maria delle Croci Hospital (Ravenna): Gianluca Zani, Maurizio Fusari; Arcispedale Sant’Anna Ferrara. (Ferrara): Savino Spadaro, Carlo A Volta; Ospedale Profili (Fabriano) (An): Romano Graziani, Barbara Brunettini; Umberto I Nocera Inferiore (Nocera Inferiore Salerno): Salvatore Palmese; Azienda Ospedaliera San Paolo – Polo Universitario- Università degli Studi di Milano (Milan): Paolo Formenti, Michele Umbrello; Sant’Anna (San Fermo Della Battaglia (Co)): Andrea Lombardo; Spedali Civili Brescia (Brescia): Elisabetta Pecci, Marco Botteri; Fondazione Irccs Ca Granda, Ospedale Maggiore Policlinico (Milan): Monica Savioli, Alessandro Protti; University Campus Bio-Medico of Rome (Rome): Alessia Mattei, Lorenzo Schiavoni; Azienda Ospedaliera “Mellino Mellini” (Chiari (Bs)): Andrea Tinnirello, Manuel Todeschini; Policlinico P. Giaccone, University of Palermo (Palermo): Antonino Giarratano, Andrea Cortegiani; Niguarda Cà Granda Hospital (Milan): Sara Sher, Anna Rossi; A.Gemelli University Hospital (Rome): Massimo M Antonelli, Luca M Montini; Ospedale “Sandro Pertini” (Rome): Paolo Casalena, Sergio Scafetti; ISMeTT IRCCS UPMC (Palermo): Giovanna Panarello, Giovanna Occhipinti; Ospedale San Gerardo (Monza): Nicolò Patroniti, Matteo Pozzi; Santa Maria Della Scaletta (Imola): Roberto R Biscione, Michela M Poli; Humanitas Research Hospital (Rozzano): Ferdinando Raimondi, Daniela Albiero; Ospedale Desio - Ao Desio-Vimercate (Desio): Giulia Crapelli, Eduardo Beck; Pinetagrande Private Hospital (Castelvolturno): Vincenzo Pota, Vincenzo Schiavone; Irccs San Martino Ist (Genova): Alexandre Molin, Fabio Tarantino; Ospedale San Raffaele (Milano): Giacomo Monti, Elena Frati; Ospedali Riuniti Di Foggia (Foggia): Lucia Mirabella, Gilda Cinnella; Azienda Ospedaliera Luigi Sacco - Polo Universitario (Milano): Tommaso Fossali, Riccardo Colombo; A.O.U. Città della Salute e della Scienza di Torino (Turin): Pierpaolo Terragni Ilaria Pattarino; Università degli Studi di Pavia-Fondazione IRCCS Policlinico San Matteo (Pavia): Francesco Mojoli, Antonio Braschi; Ao Ospedale Civile Legnano (Legnano): Erika E Borotto; Arnas Ospedale Civico Di Cristina Benfratelli (Palermo): Andrea N Cracchiolo, Daniela M Palma; Azienda Ospedaliera Della Provincia Di Lecco - Ospedale “A. Manzoni” (Lecco): Francesco Raponi, Giuseppe Foti; A.O. Provincia Di Lecco - Ospedale Alessandro Manzoni (Lecco): Ettore R Vascotto, Andrea Coppadoro; Cliniche Universitarie Sassari (Sassari): Luca Brazzi, Leda Floris; IRCCS Policlinico San Matteo (Pavia): Giorgio A Iotti, Aaron Venti
Japan: Yokohama City University Hospital (Yokohama): Osamu Yamaguchi, Shunsuke Takagi; Toyooka Hospital (Toyooka City, Hyogo Prefecture): Hiroki N Maeyama; Chiba University Hospital (Chiba City): Eizo Watanabe, Yoshihiro Yamaji; Okayma University Hospital (Okayama): Kazuyoshi Shimizu, Kyoko Shiozaki; Japanese Foundation for Cancer Research, Cancer Institute Hospital, Department Of Emergency Medicine And Critical Care (Tokyo): Satoru Futami; Ibaraki Prefectural Central Hospital (Kasama): Sekine Ryosuke; Tohoku University Hospital (Sendai-Shi): Koji Saito, Yoshinobu Kameyama; Tokyo Medical University Hachioji Medical Center (Hachioji, Tokyo): Keiko Ueno; Tokushima University Hospital (Tokushima): Masayo . Izawa, Nao Okuda; Maebashi Red Cross Hospital (Gunma Maebashi): Hiroyuki Suzuki, Tomofumi Harasawa; Urasoe General Hospital (Urasoe): Michitaka Nasu, Tadaaki Takada; Ohta General Hospital Foundation Ohta Nishinouchi Hospital (Fukushima): Fumihito Ito; Jichi Medical University Hospital (Shimotsuke): Shin - Nunomiya, Kansuke - Koyama; Mito Kyodo General Hospital, Tsukuba University Hospital Mito Medical Center (Mito): Toshikazu Abe; Sendai City Hospital (Sendai): Kohkichi Andoh, Kohei Kusumoto; Ja Hiroshima General Hospital (Hatsukaichi City, Hiroshima): Akira Hirata, Akihiro Takaba; Yokohama Rosai Hospital (Yokohama): Hiroyasu Kimura; Nagasaki University Hospital (Nagasaki): Shuhei Matsumoto, Ushio Higashijima; Niigata University Medical & Dental Hospital (Niigata): Hiroyuki Honda, Nobumasa Aoki; Mie University Hospital (Tsu, Mie): Hiroshi Imai; Yamaguchi University Hospital (Ube, Yamaguchi): Yasuaki Ogino, Ichiko Mizuguchi; Saiseikai Kumamoto Hospital (Kumamoto City): Kazuya Ichikado; Shinshu University School Of Medecine (Matsumoto City): Kenichi Nitta, Katsunori Mochizuki; Kuki General Hospital (Kuki): Tomoaki Hashida; Kyoto Medical Center (Kyoto): Hiroyuki Tanaka; Fujita Health University (Toyoake): Tomoyuki Nakamura, Daisuke Niimi; Rakwakai Marutamachi Hospital (Kyoto): Takeshi Ueda; Osaka University Hospital (Suita City, Osaka Prefecture): Yozo Kashiwa, Akinori Uchiyama
Latvia: Paul Stradins Clinical University Hospital (Riga): Olegs Sabelnikovs, Peteris Oss
Mexico: Instituto Nacional De Cancerología, México (Mexico City): Silvio A Ñamendys-Silva, Yves D Jarquin-Badiola; Hospital De Especialidades “Antonio Fraga Mouret” Centro Medico Nacional La Raza IMSS (Mexico City): Luis A Sanchez-Hurtado, Saira S Gomez-Flores; Hospital Regional 1° De Octubre (Mexico City): Maria C Marin, Asisclo J Villagomez; Hospital General Dr. Manuel Gea Gonzalez (Mexico City): Jordana S Lemus, Jonathan M Fierro; Hospital General De Zona No. 1 Instituto Mexicano Del Seguro Social Tepic Nayarit (Tepic): Mavy Ramirez Cervantes, Francisco Javier Flores Mejia; Centro Medico Dalinde (Mexico D.F.): Dulce Dector, Dulce M Dector; Opd Hospital Civil De Guadalajara Hospital Juan I Menchaca (Guadalajara): Daniel R Gonzalez, Claudia R Estrella; Hospital Regional De Ciudad Madero Pemex (Ciudad Madero): Jorge R Sanchez-Medina, Alvaro Ramirez-Gutierrez; Centro Médico ABC (Mexico D.F.): Fernando G George, Janet S Aguirre; Hospital Juarez De Mexico (Mexico City): Juan A Buensuseso, Manuel Poblano
Morocco: Mohammed V University, University Teaching Ibn Sina Hospital (Rabat): Tarek Dendane, Amine Ali Zeggwagh; Hopital Militaire D’Instruction Mohammed V (Rabat): Hicham Balkhi; Errazi (Marrakech): Mina Elkhayari, Nacer Samkaoui; University Teaching Hospital Ibn Rushd (Casablanca): Hanane Ezzouine, Abdellatif Benslama; Hôpital des Spécialités de Rabat (HSR) (Rabat): Mourad Amor, Wajdi Maazouzi
Netherlands: Tjongerschans (Heerenveen): Nedim Cimic, Oliver Beck; Cwz (Nijmegen): Monique M Bruns, Jeroen A Schouten; Rijnstate Hospital (Arnhem): Myra - Rinia, Monique Raaijmakers; Radboud Umc (Nijmegen): Leo M Heunks, Hellen M Van Wezel; Maastricht University Medical Centre (Maastricht): Serge J Heines, Ulrich Strauch; Catharinaziekenhuis (Eindhoven): Marc P Buise; Academic Medical Center (Amsterdam): Fabienne D Simonis, Marcus J Schultz
New Zealand: Tauranga Hospital (Tauranga): Jennifer C Goodson, Troy S Browne; Wellington Hospital (Wellington): Leanlove Navarra, Anna Hunt; Dunedin Hospital (Dunedin): Robyn A Hutchison, Mathew B Bailey; Auckland City Hospital (Auckland): Lynette Newby, Colin Mcarthur; Whangarei Base Hospital (Whangarei): Michael Kalkoff, Alex Mcleod; North Shore Hospital (Auckland): Jonathan Casement, Danielle J Hacking
Norway: Ålesund Hospital (Ålesund): Finn H Andersen, Merete S Dolva; Oslo University Hospital - Rikshospitalet Medical Centre (Oslo): Jon H Laake, Andreas Barratt-Due; Stavanger University Hospital (Stavanger): Kim Andre L Noremark, Eldar Søreide; Haukeland University Hospital (Bergen): Brit Å Sjøbø, Anne B Guttormsen
Peru: Hospital Nacional Edgardo Rebagliati Martins (Lima): Hector H Leon Yoshido; Clínica Ricardo Palma (Lima): Ronald Zumaran Aguilar, Fredy A Montes Oscanoa
Philippines: The Medical City (Pasig): Alain U Alisasis, Joanne B Robles; Chong Hua Hospital (Cebu): Rossini Abbie B Pasanting-Lim, Beatriz C Tan
Poland: Warsaw University Hospital (Warsaw): Pawel Andruszkiewicz, Karina Jakubowska
Portugal: Centro Hospitalar Da Cova Da Beira (Covilhã): Cristina M Coxo; Hospital Santa Maria, Chln (Lisboa): António M Alvarez, Bruno S Oliveira; Centro Hospitalar Trás-Os-Montes E Alto Douro - Hospital De S.Pedro-Vila Real (Vila Real): Gustavo M Montanha, Nelson C Barros; Hospital Beatriz Ângelo (Loures): Carlos S Pereira, António M Messias; Hospital De Santa Maria (Lisboa): Jorge M Monteiro; Centro Hospitalar Médio Tejo - Hospital De Abrantes (Abrantes): Ana M Araujo, Nuno T Catorze; Instituto Português De Oncologia De Lisboa (Lisboa): Susan M Marum, Maria J Bouw; Hospital Garcia De Orta (Almada): Rui M Gomes, Vania A Brito; Centro Hospitalar Do Algarve (Faro): Silvia Castro, Joana M Estilita; Hpp Hospital De Cascais (Alcabideche): Filipa M Barros; Hospital Prof. Doutor Fernando Fonseca Epe (Amadora): Isabel M Serra, Aurelia M Martinho
Romania: Fundeni Clinical Institute (Bucharest): Dana R Tomescu, Alexandra Marcu; Emergency Clinical County Hospital Timisoara (Timisoara): Ovidiu H Bedreag, Marius Papurica; Elias University Emergency Hospital (Bucharest): Dan E Corneci, Silvius Ioan Negoita
Russian Federation: University Hospital (Kemerovo): Evgeny Grigoriev; Krasnoyarsk Regional Hospital, Krasnoyarsk State Medical University (Krasnoyarsk): Alexey I Gritsan, Andrey A Gazenkampf
Saudi Arabia: GICU of PSMMC (Riyadh): Ghaleb Almekhlafi, Mohamad M Albarrak; SICU of PSMMC (Riyadh): Ghanem M Mustafa; King Faisal Hospital And Research Center (Riyadh): Khalid A Maghrabi, Nawal Salahuddin; King Fahad Hospital (Baha): Tharwat M Aisa; King Abdulaziz Medical City (Riyadh): Ahmed S Al Jabbary, Edgardo Tabhan; King Abdulaziz Medical City (Riyadh): Yaseen M Arabi; King Abdulaziz Medical City (Riyadh): Yaseen M Arabi, Olivia A Trinidad; King Abdulaziz Medical City (Riyadh): Hasan M Al Dorzi, Edgardo E Tabhan
South Africa: Charlotte Maxeke Johannesburg Academic Hospital (Johannesburg): Stefan Bolon, Oliver Smith
Spain: Hospital Sant Pau (Barcelona): Jordi Mancebo, Hernan Aguirre-Bermeo; Hospital Universitari Bellvitge (L Hospitalet De Llobregat (Barcelona)): Juan C Lopez-Delgado, Francisco Esteve; Hospital Son Llatzer (Palma De Mallorca): Gemma Rialp, Catalina Forteza; Sabadell Hospital, CIBER Enfermedades Respiratorias (Sabadell): Candelaria De Haro, Antonio Artigas; Hospital Universitario Central De Asturias (Oviedo): Guillermo M Albaiceta, Sara De Cima-Iglesias; Complejo Hospitalario Universitario A Coruña (A Coruña): Leticia Seoane-Quiroga, Alexandra Ceniceros-Barros; Hospital Universitario Miguel Servet (Zaragoza): Antonio L Ruiz-Aguilar, Luis M Claraco-Vega; Morales Meseguer University Hospital (Murcia): Juan Alfonso Soler, Maria del Carmen Lorente; Hospital Universitario del Henares (Coslada): Cecilia Hermosa, Federico Gordo; Complejo Asistencial De Palencia. Hospital Rio Carrión (Palencia): Miryam - Prieto-González, Juan B López-Messa; Fundación Jiménez Díaz (Madrid): Manuel P Perez, Cesar P Perez; Hospital Clínico Universitario Lozano Blesa (Zaragoza): Raquel Montoiro Allue; Hospital Verge de la Cinta (Tortosa): Ferran Roche-Campo, Marcos Ibañez-Santacruz; Hospital Universitario 12 De Octubre (Madrid): Susana - Temprano; Hospital Universitario Príncipe De Asturias (Alcalá De Henares, Madrid): Maria C Pintado, Raul De Pablo; Hospital Universitari Germans Trias I Pujol (Badalona): Pilar Ricart Aroa Gómez; Hospital Universitario Arnau De Vilanova De Lleida (Lleida): Silvia Rodriguez Ruiz, Silvia Iglesias Moles; Cst Terrassa (Barcelona): Mª Teresa Jurado, Alfons Arizmendi; Hospital Universitari Mútua Terrassa (Terrassa): Enrique A Piacentini; Hospital Universitario De Móstoles (Mostoles): Nieves Franco, Teresa Honrubia; Complejo Asistencial De Salamanca (Salamanca): Meisy Perez Cheng, Elena Perez Losada; Hospital General Universitario De Ciudad Real (Ciudad Real): Javier - Blanco, Luis J Yuste; Torrecardenas (Almeria): Cecilia Carbayo-Gorriz, Francisca G Cazorla-Barranquero; Hospital Universitario Donostia (San Sebastian): Javier G Alonso, Rosa S Alda; Hospital Universitario De Torrejón (Madrid): Ángela Algaba, Gonzalo Navarro; Hospital Universitario De La Princesa (Madrid): Enrique Cereijo, Esther Diaz-Rodriguez; Hospital Universitario Lucus Augusti (Lugo): Diego Pastor Marcos, Laura Alvarez Montero; Hospital Universitario Santa Lucia (Cartagena): Luis Herrera Para, Roberto Jimenez Sanchez; Hospital Universitario Severo Ochoa, Leganes (Madrid): Miguel Angel Blasco Navalpotro, Ricardo Diaz Abad; University Hospital Of Ntra. Sra. De Candelaria (Santa Cruz De Tenerife): Raquel Montiel Gonz á lez, D á cil Parrilla Toribio; Hospital Universitario Marques De Valdecilla (Santander): Alejandro G Castro, Maria Jose D Artiga; Hospital Infanta Cristina (Parla, Madrid): Oscar Penuelas; Hospital General De Catalunya (Sant Cugat Del Valles): Tomas P Roser, Moreno F Olga; San Pedro De Alcántara (Cáceres): Elena Gallego Curto, Rocío Manzano Sánchez; Sant Joan De Reus (Reus): Vallverdu P Imma, Garcia M Elisabet; Hospital Joan XXIII (Tarragona): Laura Claverias, Monica Magret; Hospital Universitario De Getafe (Madrid): Ana M Pellicer, Lucia L Rodriguez; Hospital Universitario Río Hortega (Valladolid): Jesús Sánchez-Ballesteros, Ángela González-Salamanca; Hospital Arquitecto Marcide (Ferrol, La Coruña): Antonio G Jimenez, Francisco P Huerta; Hospital General Universitario Gregorio Marañón (Madrid): Juan Carlos J Sotillo Diaz, Esther Bermejo Lopez; Hospital General De Segovia (Segovia): David D Llinares Moya, Alec A Tallet Alfonso; Hospital General Universitario Reina Sofia (Murcia): Palazon Sanchez Eugenio Luis, Palazon Sanchez Cesar; Complejo Hospitalario Universitario De Albacete (Albacete): Sánchez I Rafael, Corcoles G Virgilio; Hospital Infanta Elena (Valdemoro): Noelia N Recio
Sweden: Sahlgrenska University Hospital (Gothenburg): Richard O Adamsson, Christian C Rylander; Karolinska University Hospital (Stockholm): Bernhard Holzgraefe, Lars M Broman; Akademiska Sjukhuset Uppsala (Uppsala): Joanna Wessbergh, Linnea Persson; Vrinnevisjukhuset (Norrköping): Fredrik Schiöler, Hans Kedelv; Linkoping University Hospital (Linköping): Anna Oscarsson Tibblin, Henrik Appelberg; Skellefteå Lasarett (Skellefteå): Lars Hedlund, Johan Helleberg; Karolinska University Hospital Solna (Stockholm): Karin E Eriksson, Rita Glietsch; Umeå University Hospital (Umeå): Niklas Larsson, Ingela Nygren; Danderyd Hospital (Stockholm): Silvia L Nunes, Anna-Karin Morin; Lund University Hospital (Lund): Thomas Kander, Anne Adolfsson
Switzerland: Chuv (Centre Hospitalier Universitaire Vaudois) (Lausanne): Lise Piquilloud; Hôpital neuchâtelois - La Chaux-De-Fonds (La Chaux-De-Fonds): Hervé O. Zender, Corinne Leemann-Refondini
Tunisia: Hopital Taher Sfar Mahdia (Mahdia): Souheil Elatrous; University Hospital Farhat Hached Sousse (Sousse): Slaheddine Bouchoucha, Imed Chouchene; CHU F.Bourguiba (Monastir): Islem Ouanes; Mongi Slim University Hospital, La Marsa (La Marsa): Asma Ben Souissi, Salma Kamoun
Turkey: Cerrahpasa Medical Faculty Emergency Intensive Care Unit (Istanbul): Oktay Demirkiran; Cerrahpasa Medical Faculty Sadi Sun Intensive Care Unit (Istanbul): Mustafa Aker, Emre Erbabacan; Uludag University Medical Faculty (Bursa): Ilkay Ceylan, Nermin Kelebek Girgin; Ankara University Faculty of Medicine, Reanimation 3nd level ICU (Ankara): Menekse Ozcelik, Necmettin Ünal; Ankara University Faculty of Medicine, 2nd level ICU-postoperative ICU (Ankara): Basak Ceyda Meco; Istanbul Kartal Egitim Ve Arastirma Hastanesi (Istanbul): Onat O Akyol, Suleyman S Derman
UK: Papworth Hospital (Cambridge): Barry Kennedy, Ken Parhar; Royal Glamorgan Hospital (Llantrisant): Latha Srinivasa; Royal Victoria Hospital-Belfast (Belfast): Lia McNamee, Danny McAuley; Jack Steinberg ICU of the King’s College (London): Phil Hopkins, Clare Mellis; Frank Stansil ICU of the King’s College Hospital (London): Vivek Kakar; Liver ICU of the King’s College (London): Dan Hadfield; Christine Brown ICU of the King’s College (London): Andre Vercueil; West Suffolk Hospital (Bury St Edmunds): Kaushik Bhowmick, Sally K Humphreys; Craigavon Area Hospital (Portadown): Andrew Ferguson, Raymond Mckee; Barts Health NHS Trust, Whipps Cross Hospital (Leytonstone): Ashok S Raj, Danielle A Fawkes; Kettering General Hospital, Foundation NHS Trust (Northamptonshire): Philip Watt, Linda Twohey; Barnet General Hospital (Barnet): Rajeev R JhaMatthew Thomas, Alex Morton, Varsha Kadaba; Rotherham General Hospital (Rotherham): Mark J Smith, Anil P Hormis; City Hospital, (Birmingham): Santhana G Kannan, Miriam Namih; Poole Hospital NHS Foundation Trust (Poole): Henrik Reschreiter, Julie Camsooksai; Weston General Hospital (Weston-Super-Mare): Alek Kumar, Szabolcs Rugonfalvi; Antrim Area Hospital (Antrim): Christopher Nutt, Orla O’Neill; Aintree University Hospital (Liverpool): Colette Seasman, Ged Dempsey; Northern General Hospital (Sheffield): Christopher J Scott, Helen E Ellis; John Radcliffe Hospital (Oxford): Stuart Mckechnie, Paula J Hutton; St Georges Hospital (London): Nora N Di Tomasso, Michela N Vitale; Hillingdon Hospital (Uxbridge): Ruth 0 Griffin, Michael N Dean; The Royal Bournemouth & Christchurch NHS Foundation Trust (Bournemouth, Dorset): Julius H Cranshaw, Emma L Willett; Guys And St Thomas NHS Foundation Trust (London): Nicholas Ioannou, Gstt Severe Respiratory Failure Service; Whittington Hospital (London): Sarah Gillis; Wexham Park Hospital (Slough): Peter Csabi; Western General Hospital (Edinburgh): Rosaleen Macfadyen, Heidi Dawson; Royal Preston Hospital (Preston): Pieter D Preez, Alexandra J Williams; Brighton And Sussex University Hospitals NHS Trust (Brighton): Owen Boyd, Laura Ortiz-Ruiz De Gordoa; East And North Herts NHS Trust (Stevenage): Jon Bramall, Sophie Symmonds; Barnsley Hospital (Barnsley): Simon K Chau, Tim Wenham; Prince Charles Hospital (Merthyr Tydfil): Tamas Szakmany, Piroska Toth-Tarsoly; University Hospital Of South Manchester NHS Foundation Trust (Manchester): Katie H McCalman, Peter Alexander; Harrogate District Hospital (Harrogate): Lorraine Stephenson, Thomas Collyer; East And North Herts NHS Trust (Welwyn Garden City): Rhiannon Chapman, Raphael Cooper; Western Infirmary (Glasgow): Russell M Allan, Malcolm Sim; Dumfries And Galloway Royal Infirmary (Dumfries): David W Wrathall, Donald A Irvine; Charing Cross Hospital (London): Kim S Zantua, John C Adams; Worcestershire Royal Hospital (Worcester): Andrew J Burtenshaw, Gareth P Sellors; Royal Liverpool University Hospital (Liverpool): Ingeborg D Welters, Karen E Williams; Royal Alexandra Hospital (Glasgow): Robert J Hessell, Matthew G Oldroyd; Morriston Hospital (Swansea): Ceri E Battle, Suresh Pillai; Frimley Park Hospital (Frimley): Istvan Kajtor, Mageswaran Sivashanmugavel; Altnagelvin Hospital (Derry): Sinead C O’Kane, Adrian Donnelly; Buckinghamshire Healthcare NHS Trust (High Wycombe, Buckinghamshire): Aniko D Frigyik, Jon P Careless; Milton Keynes Hospital (Milton Keynes): Martin M May, Richard Stewart; Ulster Hospital (Belfast): T John Trinder, Samantha J Hagan; University Hospital of Wales (Cardiff): Matt P Wise, Jade M Cole; Freeman Hospital (Newcastle Upon Tyne): Caroline C MacFie, Anna T Dowling
Uruguay: Hospital Español (Montevideo): Javier Hurtado, Nicolás Nin; Cudam (Montevideo): Javier Hurtado; Sanatorio Mautone (Maldonado): Edgardo Nuñez; Sanatorio Americano (Montevideo): Gustavo Pittini, Ruben Rodriguez; Hospital De Clínicas (Montevideo): María C Imperio, Cristina Santos; Circulo Católico Obreros Uruguay- Sanatorio JPII (Montevido): Ana G. França, Alejandro EBEID; CASMU (Montevideo): Alberto Deicas, Carolina Serra
USA: Saint Louis University Hospital (St.Louis): Aditya Uppalapati, Ghassan Kamel; Beth Israel Deaconess Medical Center (Boston): Valerie M Banner-Goodspeed, Jeremy R Beitler; Memorial Medical Center (Springfield): Satyanarayana Reddy Mukkera, Shreedhar Kulkarni; Massachusetts General Hospital (Boston): Jarone Lee, Tomaz Mesar; University Of Cincinnati Medical Center (Cincinnati): John O Shinn 3rd, Dina Gomaa; Massachusetts General Hospital (Boston): Christopher Tainter, Jarone Lee; Massachusetts General Hospital (Boston): Tomaz Mesar, Jarone Lee; R Adams Cowley Shock Trauma Center (Baltimore): Dale J Yeatts, Jessica Warren; Intermountain Medical Center (Murray, Utah): Michael J Lanspa, Russel R Miller; Intermountain Medical Center (Murray, Utah): Colin K Grissom, Samuel M Brown; Mayo Clinic (Rochester): Philippe R Bauer; North Shore Medical Center (Salem): Ryan J Gosselin, Barrett T Kitch; Albany Medical Center (Albany): Jason E Cohen, Scott H Beegle; John H Stoger Hospital Of Cook County (Chicago, Il): Renaud M Gueret, Aiman Tulaimat; Albany Medical Center (Albany): Shazia Choudry; University of Alabama at Birmingham (UAb) (Birmingham, AL): William Stigler, Hitesh Batra; Duke University Hospital (Durham): Nidhi G Huff; Iowa Methodist Medical Center (Des Moines, Iowa): Keith D Lamb, Trevor W Oetting; Surgical & Neurosciences Intensive Care Unit of the University Of Iowa Hospitals And Clinics (Iowa City, Iowa): Nicholas M Mohr, Claine Judy; Medical Center of Louisiana at New Orleans (New Orleans, Louisiana): Shigeki Saito, Fayez M Kheir; Tulane University (New Orleans): Fayez Kheir; Critical Care Unit of the University Of Iowa Hospitals And Clinics (Iowa City, Iowa): Adam B Schlichting, Angela Delsing; University Of California, San Diego Medical Center (San Diego, Ca): Daniel R Crouch, Mary Elmasri; Uc San Diego Thornton Hospital (La Jolla): Daniel R Crouch, Dina Ismail; University Hospital (Cincinnati): Kyle R Dreyer, Thomas C Blakeman; University Hospital (Cincinnati): Kyle R Dreyer, Dina Gomaa; Tower 3B Medical ICU of Brigham and Women’s Hospital (Boston): Rebecca M Baron, Carolina Quintana Grijalba; Tower 8C Burn/Trauma ICU of Brigham and Women’s Hospital (Boston): Peter C Hou; Tower 8D Surgical ICU of Brigham and Women’s Hospital (Boston): Raghu Seethala; Tower 9C Neurosurgical ICU of Brigham and Women’s Hospital (Boston): Imo Aisiku; Tower 9D Neurological ICU of Brigham and Women’s Hospital (Boston): Galen Henderson; Tower 11C Thoracic ICU of Brigham and Women’s Hospital (Boston): Gyorgy Frendl; Shapiro 6W Cardiac Surgery ICU of Brigham and Women’s Hospital (Boston): Sen-Kuang Hou; Shapiro 9E Coronary Care Unit of Brigham and Women’s Hospital (Boston): Robert L Owens, Ashley Schomer
Serbia: Clinical Center of Serbia (Belgrade): Vesna Bumbasirevic, Bojan Jovanovic; Military Medical Academy (Belgrade): Maja Surbatovic, Milic Veljovic
Ethics approval and consent to participate
All participating ICUs obtained ethics committee approval and obtained either patient consent or ethics committee waiver of consent in LUNG SAFE study. The study protocol was also reviewed and approved by the ethics committee of Mito Kyodo General Hospital, University of Tsukuba Hospital Mito Medical Center, Japan.
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Hyperoxemia and excess oxygen use in early acute respiratory distress syndrome: insights from the LUNG SAFE study
verfasst von
Fabiana Madotto Emanuele Rezoagli Tài Pham Marcello Schmidt Bairbre McNicholas Alessandro Protti Rakshit Panwar Giacomo Bellani Eddy Fan Frank van Haren Laurent Brochard John G. Laffey for the LUNG SAFE Investigators and the ESICM Trials Group
